2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.
Tony SK Mok, MD, chairman, Department of Clinical Oncology, Li Shu Fan Professor of Clinical Oncology, fellow of ASCO (FASCO), member, ASCO Board of Director, member, The Hong Kong Academy of Sciences, discusses the rationale for the phase 1 U31402-A-U102 trial (NCT03260491) in metastatic or unresectable non–small cell lung cancer (NSCLC).
U31402-A-U102 examined the safety and antitumor efficacy of patritumab deruxtecan (U3-1402) in a 2-part trial consisting of dose escalation and dose expansion in patients with NSCLC. The trial found resulted in a recommended phase 2 dose 5.6 mg/kg, Mok says.
Moreover, patritumab deruxtecan elicited an overall response rate of 39% and a median progression-free survival of 8.2 months across all doses, Mok continues. In this heavily pretreated patient population, the median number of prior systemic therapies was 4, including previous TKI and chemotherapy, Mok adds. Despite prior treatment, the patients achieved impressive outcomes, setting the stage for future studies, Mok concludes.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.